Octahydropentalene compounds as chemokine receptor antagonists
    8.
    发明授权
    Octahydropentalene compounds as chemokine receptor antagonists 有权
    八氢化合物作为趋化因子受体拮抗剂

    公开(公告)号:US07939544B2

    公开(公告)日:2011-05-10

    申请号:US12284758

    申请日:2008-09-25

    摘要: The present invention is directed to novel compounds of Formula (I) pharmaceutically acceptable salts thereof, pro-drugs thereof, biologically active metabolites thereof, isomers thereof or stereoisomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, osteoarthritis, multiple sclerosis and asthma.

    摘要翻译: 本发明涉及新的式(I)化合物,其药学上可接受的盐,其前药,其生物活性代谢物,其异构体或其立体异构体,其中变量如本文所定义。 式(I)的化合物可用作趋化因子受体拮抗剂,因此可用于治疗某些病症和疾病,特别是炎性病症和疾病以及增殖性疾病和病症,例如类风湿性关节炎,骨关节炎,多发性硬化和哮喘。